In last trading session, NewAmsterdam Pharma Company NV (NASDAQ:NAMS) saw 0.57 million shares changing hands with its beta currently measuring -0.06. Company’s recent per share price level of $18.57 trading at -$0.43 or -2.26% at ring of the bell on the day assigns it a market valuation of $1.98B. That closing price of NAMS’s stock is at a discount of -46.96% from its 52-week high price of $27.29 and is indicating a premium of 18.2% from its 52-week low price of $15.19.

For NewAmsterdam Pharma Company NV (NAMS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.47 in the current quarter.

NewAmsterdam Pharma Company NV (NASDAQ:NAMS) trade information

Upright in the red during last session for losing -2.26%, in the last five days NAMS remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $18.57 price level, adding 9.24% to its value on the day. NewAmsterdam Pharma Company NV’s shares saw a change of -27.74% in year-to-date performance and have moved -4.28% in past 5-day. NewAmsterdam Pharma Company NV (NASDAQ:NAMS) showed a performance of -20.54% in past 30-days.

Wall Street analysts have assigned a consensus price target of 41 to the stock, which implies a rise of 54.71% to its current value. Analysts have been projecting 36 as a low price target for the stock while placing it at a high target of 48. It follows that stock’s current price would drop -93.86% in reaching the projected high whereas dropping to the targeted low would mean a loss of -93.86% for stock’s current value.

NewAmsterdam Pharma Company NV (NAMS) estimates and forecasts

This year revenue growth is estimated to rise 139.40% from the last financial year’s standing.

10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.67M for the same. And 7 analysts are in estimates of company making revenue of 2.53M in the next quarter.

In 2025, company’s earnings growth rate is likely to be around 5.52% while estimates for its earnings growth in next 5 years are of 7.70%.

NewAmsterdam Pharma Company NV (NASDAQ:NAMS)’s Major holders

FRAZIER LIFE SCIENCES MANAGEMENT, L.P. is the top institutional holder at NAMS for having 12.23 million shares of worth $234.88 million. And as of 2024-06-30, it was holding 12.9097 of the company’s outstanding shares.

The second largest institutional holder is FCPM III SERVICES B.V., which was holding about 11.83 million shares on 2024-06-30. The number of shares represents firm’s hold over 12.4921 of outstanding shares, having a total worth of $227.28 million.

On the other hand, AB Cap Fd.-AB Small Cap Growth Port and PGIM Jennison Health Sciences Fd are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 573.26 shares of worth $10.65 million or 0.62% of the total outstanding shares. The later fund manager was in possession of 489.12 shares on Nov 30, 2024 , making its stake of worth around $9.08 million in the company or a holder of 0.53% of company’s stock.